Treatment Paradigms In AMD Management Webinar Part 3 -

Name: Treatment Paradigms In AMD Management Webinar Part 3
Uploaded: 2018-04-24T08:00:00+00:00
Duration: 42 min 41 s
Description: This continuing medical education activity is supported through an independent educational grant from Regeneron Pharmaceuticals, Inc.

Media formats available:

Details

Presenters

Overview
This continuing medical education activity is supported through an independent educational grant from Regeneron Pharmaceuticals, Inc.
Learning Objectives
Learning objectives Upon completion of this activity, participants will be better able to:
- Understand the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and RVO
- Discuss the outcomes of pivotal studies in AMD, DME, and RVO and how study results may differ from “real-world” dosing methods
- Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe
- Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations.
Accreditation
Accreditation Statement Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit Designation Statement Evolve designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Ivan J. Suner, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences; Allergan plc; Santen; and Genentech. Grant/Research Support: Allergan plc; and Genentech. Speaker's Bureau: Genentech; and Regeneron Pharmaceuticals.Editorial Support Disclosures Erin K. Fletcher, MIT, director of compliance and education, Evolve; and Michelle Dalton, writer, have no financial relationships with commercial interests. Jaya Kumar, MD, peer reviewer, has no financial relationships with commercial interests.
Disclaimer
Off-Label Statement This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve Medical Education LLC, or Regeneron Pharmaceuticals Inc.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 04/24/2018
Expiration Date: 04/30/2019